Platform Expansion Roadmap
Systematic expansion across all areas of hematology, building on our proven AML and MDS foundation.
Completed Platforms
Acute Myeloid Leukemia
WHO 2022 & ICC 2022 classification with ELN risk stratification
Myelodysplastic Syndromes
Comprehensive classification and IPSS-R risk assessment
Currently In Development
Chronic Lymphocytic Leukemia
B-cell chronic leukemia with iwCLL staging and prognostic markers
Planned Expansion
Acute Lymphoblastic Leukemia
Pediatric and adult ALL classification with risk stratification
Chronic Myelomonocytic Leukemia
Myelodysplastic/myeloproliferative neoplasm with prognostic scoring
Chronic Myeloid Leukemia
BCR-ABL positive leukemia with response monitoring
Diffuse Large B-Cell Lymphoma
Aggressive B-cell lymphoma with molecular subtyping
Follicular Lymphoma
Indolent B-cell lymphoma with grading and risk assessment
Hodgkin Lymphoma
Classical and nodular lymphocyte-predominant Hodgkin lymphoma
Mantle Cell Lymphoma
Aggressive B-cell lymphoma with prognostic markers
Marginal Zone Lymphomas
MALT, nodal, and splenic marginal zone lymphomas
Burkitt Lymphoma
Highly aggressive B-cell lymphoma with molecular confirmation
Peripheral T-Cell Lymphomas
Heterogeneous group of mature T-cell neoplasms
Cutaneous Lymphomas
Primary cutaneous B-cell and T-cell lymphomas
Plasma Cell Disorders
Multiple myeloma, MGUS, and related plasma cell neoplasms
Hairy Cell Leukemia
Rare B-cell leukemia with characteristic morphology
Myeloproliferative Neoplasms
BCR-ABL negative MPNs including PV, ET, and PMF
Mastocytosis
Clonal mast cell disorders with KIT mutations
Bone Marrow Failure Syndromes
Aplastic anemia and inherited bone marrow failure syndromes
Histiocytic Disorders
Langerhans cell histiocytosis and related disorders